Tag Archives: Mayank Mamtani

Dicerna Pharma (DRNA) Gets a Buy Rating from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Dicerna Pharma (DRNA – Research Report), with a price target of $24. The company’s shares closed on Friday at $13.59. Mamtani noted: “Pharmaceuticals (DRNA) reported

IMV Inc. (IMV) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on IMV Inc. (IMV – Research Report) today and set a price target of $11. The company’s shares closed on Friday at $2.40, close to its 52-week low of $2.25. Mamtani

Madrigal Pharmaceuticals Inc (MDGL) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report) on August 9 and set a price target of $134. The company’s shares closed on Friday at $89.66, close to its 52-week low

Intercept Pharma (ICPT) Gets a Buy Rating from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Intercept Pharma (ICPT – Research Report), with a price target of $133. The company’s shares closed yesterday at $61.51, close to its 52-week low of

B.Riley FBR Thinks Viking Therapeutics’ Stock is Going to Recover

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $16. The company’s shares closed yesterday at $7.57, close to its 52-week low of

B.Riley FBR Keeps a Buy Rating on Medicines Co (MDCO)

B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Medicines Co (MDCO – Research Report) today and set a price target of $61. The company’s shares closed yesterday at $36.52. Mamtani commented: “The Medicines Company (MDCO) remains the most